A naturally occurring compound found in a wide variety of plants. There are several benefits when used locally.
No products
A naturally occurring compound found in a wide variety of plants. There are several benefits when used locally.
Gallic Acid — topical skin-care benefits (with selected recent research)
| Benefit cluster | Representative mechanisms & key findings | Strength of evidence* |
|---|---|---|
| Antioxidant & photo-protection / anti-photo-aging | • 0.1–1 mM GA prevented UVB-induced ROS, lipid peroxidation and MMP-1/-3 up-regulation in human fibroblasts; topical 0.5 % GA cream reduced wrinkle depth and dermal collagen loss in hairless-mouse UVB model pubmed.ncbi.nlm.nih.gov | Animal + in-vitro |
| Anti-inflammatory (psoriasis, irritant skin) | • GA (25–50 µM) suppressed MAPK/NF-κB signalling and IL-6/IL-8 release in HaCaT keratinocytes banglajol.info • 20 µM GA lowered IFN-γ⁺ and IL-17⁺ T-cell fractions in PBMCs from psoriasis patients pmc.ncbi.nlm.nih.gov | Ex-vivo human cells |
| Atopic-dermatitis relief / barrier support | • 20 mg kg⁻¹ topical GA reduced ear thickness, erythema, serum IgE and TNF-α in DNCB-induced AD mouse model; down-regulated Th17/STAT3 axis pmc.ncbi.nlm.nih.gov | Animal |
| Wound healing & scar reduction | • GA nanocrystal hydrogel accelerated re-epithelialisation, increased tensile strength and lowered α-SMA/scar index in rat full-thickness wounds; sustained GA release over 48 h pubmed.ncbi.nlm.nih.gov | Animal |
| Anti-acne (antibacterial, sebum modulation) | • Chitosan-coated GA aspasomes (≈300 nm) showed 3-log CFU reduction against C. acnes, inhibited IL-8 in sebocytes and reduced lesion count by 38 % in a 4-week split-face pilot (n = 20) pubmed.ncbi.nlm.nih.gov | Pilot clinical |
| Skin-lightening / tyrosinase inhibition | • GA (50–100 µM) cut intracellular tyrosinase activity & melanin content 30–50 % in B16F10 melanocytes; down-regulated MITF via PI3K/Akt & ERK activation pmc.ncbi.nlm.nih.gov | In-vitro |
*Evidence grading (high-level):
In-vitro = cell culture data; Ex-vivo human = cells from patients; Animal = rodent or zebrafish skin models; Pilot clinical = small controlled human study.
Solubility: GA is water-soluble (~12 mg mL⁻¹ at 25 °C) but oxidises easily; work below pH < 6 and exclude oxygen/metal ions (add 0.05 % EDTA, N₂ blanket).
Stability enhancers: Micro- or nano-encapsulation (liposomes, aspasomes, nanocrystals) markedly improves skin penetration and photostability (see acne & wound-healing studies).
Synergies: Combining GA with vitamin C or ferulic acid reinforces antioxidant capacity; pairing with niacinamide supports barrier recovery in AD-prone skin.
Regulatory / safety: GA is on EU CosIng as “skin-conditioning/antioxidant”; typical cosmetic levels 0.05–0.5 %. In recent patch tests up to 1 % was non-sensitising.
Use: for anti-aging products in any form
How to mix: added in the last step of the formula Avoid using heat. Maximum water soluble 1%, formula should contain Disodium EDTA.
Utilization rate: 0.1-1.0%
Product characteristics: white-light powder
Solubility: can dissolve in water
Storage: Store in the refrigerator (5-10 degrees). Do not expose to any kind of light. avoid air At least 24 months old
INCI Name : Gallic Acid
Examples of products that use Gallic Acid
ReVive INTENSITE COMPLETE Anti-Aging Serum
Dr.Dennis Gross Ferulic + Retinol Anti-Aging Moisturizer
StriVectin Glycolic Skin Reset Mask
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
